Daily news about corporate social responsibility, ethics and sustainability
Tags (5) : biologics
Kaigene Licenses KG006 Autoimmune Drug to Taisho for Japan
07/31/2026 | Companies
antibody therapeutics,
autoimmune disease treatment,
autoimmune disorders,
autoimmune therapy,
biologics,
biotech licensing,
biotechnology,
Celltrion,
clinical development,
drug commercialization,
drug licensing agreement,
FcRn inhibitor,
healthcare news,
hFcRn inhibitor,
immunology,
innovative therapeutics,
Japan pharmaceutical market,
Japanese pharma,
Kaigene,
KG006,
milestone payments,
MRCT,
Multi-Regional Clinical Trial,
neonatal Fc receptor,
next-generation antibodies,
pharmaceutical partnership,
Phase 3 clinical trial,
regulatory approval,
royalty agreement,
Taisho Pharmaceutical
AsymBio Expands Biologics CDMO with New Shanghai R&D Center
07/27/2026 | Companies
AccPCC,
ADC,
AI-enabled platform,
analytical development,
antibodies,
antibody-drug conjugates,
AsymBio,
Asymchem Group,
biologics,
biologics development,
biologics manufacturing,
biopharmaceuticals,
biotech partnerships,
biotechnology,
CDMO,
cell line development,
chemistry manufacturing and controls,
clinical manufacturing,
CMC,
commercial manufacturing,
conjugation process,
contract development,
contract manufacturing,
downstream processing,
drug development,
drug product development,
Fengxian,
global biotech,
green building,
innovation,
life sciences,
low-carbon infrastructure,
manufacturing excellence,
PCC selection,
pharmaceutical manufacturing,
pharmaceutical research,
preclinical candidate,
process development,
R&D expansion,
R&D facility,
research and development,
scale-up manufacturing,
science to clinic,
Shanghai,
sustainable construction,
technology transfer,
translational research,
upstream processing
Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation
04/28/2026 | Companies
Abu Dhabi,
Alzheimer’s disease,
Arcera Life Sciences,
biologics,
biotechnology,
biotechnology incubation,
cardiometabolic diseases,
cell therapy,
China,
drug development,
emerging markets,
Fosun Pharma,
gene therapy,
global healthcare,
healthcare infrastructure,
innovation,
international collaboration,
joint ventures,
licensing,
life sciences,
market access,
memorandum of understanding,
Middle East healthcare,
MoU,
neurodegenerative diseases,
neuroscience,
oncology,
pharmaceutical industry,
R&D,
radiopharmaceuticals,
rare diseases,
research and development,
siRNA therapies,
small molecules,
strategic partnership,
UAE,
Vision 2030
Harbour BioMed Reports Positive Phase I Results for HBM9378 Antibody Therapy
03/23/2026 | Companies
antibody therapeutics,
biologics,
biotech innovation,
chronic obstructive pulmonary disease,
clinical research,
COPD,
drug development,
half-life extension,
Harbour BioMed,
HBM9378,
immune-oncology,
immunological disorders,
immunology,
Kelun-Biotech,
monoclonal antibody,
pharmacokinetics,
Phase I clinical trial,
respiratory medicine,
safety profile,
severe asthma,
SKB378,
TSLP inhibitor,
WIN378
Teva’s Global Innovation Strategy: Advancing Healthcare Through Collaboration and Research
06/18/2025 | Companies
academic partnerships,
academic research,
AI drug development,
AI in healthcare,
AION Labs,
BioInnovators Forum,
biologics,
biomarkers,
clinical trials,
disease burden,
drug discovery,
epidemiology,
healthcare access,
healthcare innovation,
IMI,
innovation,
Israeli biotech,
medical education,
neurodegenerative diseases,
Organospheres,
patient access,
pharmaceutical research,
pharmaceutical startups,
public health research,
public-private partnerships,
PubMed publications,
R&D,
scientific collaboration,
Teva Pharmaceuticals,
translational medicine,
unmet medical needs
Companies
Most Popular Now
Environment News
Compliance
Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com